Related Experiment Video

Updated: Sep 11, 2026

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

First line asciminib in chronic myeloid leukemia: a quest for the "Holy Grail" of tolerability

Delphine Rea1

  • 1Saint-Louis University Hospital. delphine.rea@sls.aphp.fr.

Haematologica
|September 10, 2026
PubMed

Abstract:

Not available.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

Related Experiment Videos

Last Updated: Sep 11, 2026

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Articles linked to this work by shared authors, journal, and citation graph.

Reframing chronic myeloid leukemia outcomes beyond survival: a perspective of quality of life and patient-centered data.

Blood reviews·2026

Clonal and genomic determinants of e1a2 BCR::ABL1 chronic myeloid leukemia: A Fi-LMC study.

HemaSphere·2026

Asciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final results.

Leukemia·2026

From fatal disease to functional cure: 25 years of tyrosine kinase inhibition in chronic myeloid leukemia.

Leukemia·2026

Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial.

The Lancet. Haematology·2026

Extended long-term follow-up and the survival of Stop Imatinib study.

Blood neoplasia·2026

Early measurement of ST2 and REG3α has a prognostic impact in haploidentical transplantation with post-transplant cyclophosphamide.

Haematologica·2026

The double-edged sword of Plasmodium falciparum: malaria and a predisposition to B-cell malignancy?

Haematologica·2026

Venetoclax plus azacitidine in younger adults with acute myeloid leukemia beyond historical comparisons. Comment on: "Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy".

Haematologica·2026

Beyond exclusion: the case for genetic screening in immune thrombocytopenia.

Haematologica·2026

Hyperinflammatory differentiation syndrome with hemophagocytic lymphohistiocytosis-like features following menin inhibition in acute myeloid leukemia.

Haematologica·2026

Neutrophil extracellular traps and DNase I levels in the bronchoalveolar lavage fluid of children with pulmonary injury after allogeneic hematopoietic stem cell transplantation: a TRANSPIRE study.

Haematologica·2026

Prolonged, transplant-free remission with tagraxofusp in combination with venetoclax for transplant-ineligible blastic plasmacytoid dendritic cell neoplasm.

Leukemia research reports·2026

Examining intersections of biographies & biologies: Diversity & outcomes of people with multiple sclerosis in Canada (iBio2Div-MS) protocol.

Multiple sclerosis and related disorders·2026

Baseline MRI markers and clinical outcomes during anti-amyloid β therapy: A real-world study in a Japanese dementia center.

The journal of prevention of Alzheimer's disease·2026

Polymeric and metallic occluders for interventional therapy of cardiovascular diseases.

Biomaterials·2026

No effect of transcranial direct current stimulation on brain age during cognitive behavioral therapy for major depressive disorder: secondary results from a randomized, double-blind, sham-controlled trial.

Journal of psychiatric research·2026

Optimizing Endosomal Escape for Effective Aptamer-Based Ubiquitin-Mediated Degradation of c-Met.

ACS applied materials & interfaces·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us